regulation of proliferation, apoptosis, or senescence, at least in vitro (20) , little is known about the specific activities of each isoform. PML has been highlighted as a transcriptional coregulator, since it associates with several transcription factors and cofactors (40) . Despite the ubiquitous expression of PML proteins and the variety of binding partners, PML-deficient (PML Ϫ/Ϫ ) mice do not display significant phenotypes, suggesting that they are not required for but rather modulate normal development. Interestingly, however, the terminal differentiation of granuloid and monocytoid cell lineages is impaired in PML Ϫ/Ϫ mice (32) , but how this occurs remains to be elucidated.
Granulopoiesis is a tightly regulated developmental process that begins with the commitment of myeloid precursors followed by their terminal differentiation, a process that requires cooperative or stepwise actions of lineage-specific transcription factors (6) . PU.1 is expressed exclusively in hematopoietic cells (13) , and it binds to a purine-rich DNA sequence containing the 5Ј-GGAA/T-3Ј core motif. Although the targeted disruption of the PU.1 gene can cause multiple hematopoietic aberrations, it invariably causes a defect in the terminal differentiation of myeloid cells (5, 19, 22, 27) . PU.1 associates with the p300/CREB-binding protein (CBP) coactivator, at least in vitro (33) ; however, its essential protein-protein interactions during granulocytic terminal differentiation remain to be explored. PU.1 regulates many myeloid cell-specific genes, including cytokine receptors for granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factor, but the transcriptional cascade that underlies the cell-autonomous effects of PU.1 remains to be elucidated.
CCAAT/enhancer-binding protein ε (C/EBPε) is expressed exclusively in granuloid cells and is essential for the terminal differentiation of committed granulocyte progenitors (17, 34a) . C/EBPε is thought to be one critical target of PML-RARA. This is strongly supported by the following observations: (i) C/EBPε is directly regulated by RARA (23) ; (ii) PML-RARA inhibits the expression of C/EBPε, whereas ATRA restores it (23) ; (iii) the introduction of C/EBPε into APL cells can mimic the ability of ATRA to drive granulocyte differentiation in vitro and repress the leukemic phenotype of APL in vivo (29) ; and (iv) APL cells lack secondary granules, which is the prominent characteristic of APL cells and is consistent with a deregulation of C/EBPε expression (7, 34a) .
To clarify the role of PML-RARA in the pathogenesis of APL, especially how it causes the arrest of granulocytic differentiation, we focused on the biological properties of PML-RARA and how it perturbs PML function. We show for the first time that the impaired granulopoiesis in PML Ϫ/Ϫ mice is associated with the reduced expression of C/EBPε. In addition, PU.1 directly regulates C/EBPε expression, and PML modulates it by promoting the formation of a PU.1/p300 complex in an isoform-specific manner. Finally, we show that PML-RARA can block granulopoiesis by the direct transrepression of a PU.1/PML/p300 ternary complex and propose a model for how PML-RARA acts as a dominant-negative inhibitor of PMLinduced transcription. These results should provide a new insight into how PML-RARA causes leukemia and should help identify new molecular targets for the treatment of APL.
MATERIALS AND METHODS
Mice and cell lines. PML-deficient mice were generated as described previously (32) . Mice over 40 weeks of age were analyzed. All animals were maintained under specific-pathogen-free, temperature-controlled conditions throughout this study, in accordance with institutional guidelines. Written approval for all animal experiments was obtained from the local Animal Experiments Committee of the National Cancer Center Research Institute.
Interleukin-3-dependent myeloid L-G myeloblasts (16) and BOSC23, NIH 3T3, and HeLa cells were obtained from the Japanese Cancer Research Bank (Osaka, Japan).
Flow cytometric analysis. Bone marrow (BM) and peripheral blood cells were prepared by lysing erythrocytes in ammonium chloride buffer. In general, one million cells were incubated on ice for 45 min with the appropriate staining reagents according to standard methods. The reagents used in this study were as follows: peridinin chlorophyll protein-cyanin 5.5-conjugated streptavidin, antiMac-1-fluorescein isothiocyanate (M1/70-fluorescein isothiocyanate), anti-cKit-allophycocyanin (2B8-allophycocyanin), and anti-Gr-1-biotin (RB6-8C5-biotin). All of the reagents were purchased from Pharmingen (La Jolla, CA). Flow cytometry was performed by using a FACSCalibur apparatus (Becton Dickenson), and the results were analyzed using CELLQUEST software (Becton Dickenson).
Expression vectors. Human cDNAs encoding FLAG-or hemagglutinin (HA)-tagged PML isoforms I, II, III, IV, V, and VI were cloned into pLNCX and pLPCX retroviral mammalian expression vectors as described elsewhere previously (21) . The cDNAs for PU.1, PML-RARA, PLZF-RARA, RAR, and retinoid X receptor were kindly provided by Francoise Moreau-Gachelin, Akira Kakizuka, Zu Chen, and Pierre Chambon, respectively. The deletion mutants for PU.1 and PML were constructed by PCR-mediated methods (see the supplemental material). The cDNAs for FLAG-tagged PU.1 and its deletion mutants were cloned into the metallothionein promoter-driven expression vector pMT-CB6ϩ. The PML-RARA cDNA was cloned into the pcDNA3.1/His vector (Invitrogen, Carlsbad, CA) for Xpress tagging. HA-tagged PML-RARA cDNA was also cloned into the puromycin-resistant vector pMT-CB6ϩpuro. HA-or FLAGtagged p300 expression vectors were described previously (21) .
Construction of L-G myeloblast clones. L-G cells (1 ϫ 10 7 ) were transfected with 10 g of PvuI-linearized plasmid pMT-CB6ϩ/PU.1 (FLAG tagged) or its deletion derivatives by electroporation (960 F, 0.35 kV). Stable clones were selected by the treatment of the cells with 1 mg/ml of G418. The expression of PU.1 was induced with 100 M of ZnSO 4 and verified by Western blotting.
Retroviruses were prepared from BOSC23 cells transfected with vector pLPCX encoding HA-tagged PML isoforms I to VI or C-terminal deletion mutants of PML IV, and bulk populations were selected by treatment with 0.6 g/ml of puromycin.
Antibodies. The following antibodies were used in this study: anti-PU.1 (T-21 rabbit polyclonal; Santa Cruz Biotechnology, Santa Cruz, CA), anti-FLAG (M2 mouse monoclonal; Sigma, St. Louis, MO), anti-p300 (NM11 mouse monoclonal; BD Bioscience, San Diego, CA;), anti-HA (3F10 rat monoclonal; Roche Diagnostics, Mannheim, Germany), anti-C/EBPε (C-22 rabbit polyclonal; Santa Cruz Biotechnology), anti-TFIIB (C-18 rabbit polyclonal; Santa Cruz Biotechnology), and anti-PML (PML001 rabbit polyclonal and 1B4 mouse monoclonal [MBL, Nagoya, Japan] and H-238 rabbit polyclonal [Santa Cruz Biotechnology]).
Immunoprecipitation and Western blotting. Detailed procedures for sample preparation, immunoprecipitation, and Western blotting were described elsewhere previously (21) .
Immunostaining. Indirect immunofluorescence was performed as previously described (21) .
EMSA. An electrophoretic mobility shift assay (EMSA) was performed according to standard procedures (see the supplemental materials for details). For supershift assays, an anti-PU.1 polyclonal antibody (Santa Cruz Biotechnology) was used.
ChIP. Chromatin immunoprecipitation (ChIP) was performed according to the manufacturer's instructions (UBI, Lake Placid, NY) by using the following primers: 5Ј-CCCATGAGTACCTATATGCTCA-3Ј and 5Ј-CTCAAATCTGGC CTCCGTCACTG-3Ј for region 1, 5Ј-AAGGCTTACATCTCTCCCTCTG-3Ј and 5Ј-CTGTCACCCACTCCTGTGTG-3Ј for region 2, and 5Ј-CACACGATT GTTTAGAGGTAGAAC-3Ј and 5Ј-GAGACTTTAAGAAGCCCGTAATC-3Ј for region 3.
Luciferase reporter assay. The C/EBPε promoter region was amplified by genomic PCR and cloned into the pGL3-Basic vector (Promega, Madison, WI) as described previously (34) . The putative PU.1 binding sites were mutated by site-directed mutagenesis according to standard procedures (see the supplemental material for details). The cells were transfected with the aid of Effectene transfection reagent according to the manufacturer's instructions (QIAGEN, Valencia, CA). After 36 h, luciferase activity was determined using a Dual Luciferase assay system (Promega) according to the manufacturer's instructions. Values were normalized by the luciferase activity of a cotransfected Renilla luciferase-expressing vector (pRL-CMV).
RT-PCR. RNA was isolated according to standard protocols and reverse transcribed with random primer using Superscript II (Invitrogen) according to the manufacturer's instructions. For quantitative reverse transcription (RT)-PCR, the following sets of primers and internal fluorescence probes were purchased from Roche Diagnostics (Indianapolis, IN); mouse C/EBPε (catalog no. 04688970001), mouse GAPDH (catalog no. 04689089001), and mouse PML (catalog no. 04688996001). PCRs were performed using an ABI PRISM 7500 Fast Real-Time RCR system (Perkin-Elmer, Foster City, CA) using TaqMan Universal PCR Master Mix containing specific primers (1.2 M) and a specific probe (0.1 M). For conventional RT-PCR, the following sets of primers were used: 5Ј-GACTACAAAGACGATGACGAC-3Ј (forward) and 5Ј-CAGTAATGGTC GCTATGGCTC-3Ј (reverse) for FLAG-tagged human PU.1 and 5Ј-CTTCACC ACCATGGAGAAGG-3Ј (forward) and 5Ј-GGCATGGACTGTGGTCATGA G-3Ј (reverse) for GAPDH.
RESULTS
Impaired granulopoiesis and reduced C/EBP expression in PML-deficient mice. Flow cytometry analysis of sex-matched littermates revealed that circulating Gr-1 hi Mac-1 ϩ mature granulocytes were reduced in peripheral blood from PML Ϫ/Ϫ mice (Fig. 1A) , as previously described (32) . On the other hand, the increase of immature granulocytes in the BM of PML Ϫ/Ϫ mice was demonstrated by a fourfold increase in Gr-1 ϩ c-Kit ϩ cells (Fig. 1B) . These results suggest that the terminal maturation of granulocytes is impaired in PML Ϫ/Ϫ mice. To investigate the role of PML in normal granulopoiesis, we examined the expression levels of several transcription factors that are supposed to be essential for the process. Western blotting analysis of BM mononuclear cells revealed that PML expression was reduced in proportion to the PML genotype.
There was no significant difference in PU.1 and C/EBP␣, but C/EBP␤ expression was modestly reduced in PML Ϫ/Ϫ mice. On the other hand, C/EBPε expression was reduced in proportion to that of PML (Fig. 1C) . These results suggest that the specific involvement of PML in C/EBPε expression may account for its underlying role in granulocytic differentiation.
C/EBP is a direct transcriptional target of PU.1. To investigate how PML is involved in C/EBPε expression, we first analyzed its promoter. The transcription of the C/EBPε gene is regulated mainly by the downstream P␤ promoter, which is highly conserved among different species (2, 34) . The DNA sequence around the P␤ promoter is highly rich in purine tracts, which are peculiar features of myeloid cell-specific genes and often serve as potential binding sites for ets family transcription factors. These facts prompted us to examine if PU.1 regulates the expression of C/EBPε. ChIP assays of HL-60 cells revealed that PU.1 binds to the region 2, which includes the P␤ promoter, in vivo ( Fig. 2A) . However, we could not detect any significant binding of PU.1 to other genomic regions 4 kb upstream or downstream of the P␤ promoter (regions 1 and 3, respectively). These results indicate that PU.1 binds to a specific genomic region that includes the P␤ promoter. The specificity of this ChIP assay was further confirmed, as the same anti-PU.1 antibody failed to precipitate region 2 in MOLT-4 cells that lack endogenous PU.1 expression (see Fig. S1A in the supplemental material). EMSA detected at least two PU.1 binding regions: region A, between bp Ϫ80 and Ϫ44, and region B, between bp Ϫ40 and Ϫ18. PU.1 bound to region A more efficiently than region B (Fig. 2D,  left) . Inspection of the DNA sequence identified six putative ets core motifs (A1 to A3 and B1 to B3) (Fig. 2C) . To identify the PU.1 binding sites, we constructed a C/EBPε promotercontaining luciferase reporter, introduced either several block mutations or various combinations of site-directed mutations into these motifs, and performed transactivation assays using NIH 3T3 cells (Fig. 2E) . As we expected, the response to PU.1 was limited to a region between bp Ϫ80 and Ϫ18, which contains a purine-rich tract. Luciferase assays further revealed that the response to PU.1 was mediated between positions bp Ϫ62 and Ϫ57 (A2) and between bp Ϫ34 and Ϫ29 (B1) (Fig. 2E) . Similar results were also obtained for HeLa cells (see Fig. S1B in the supplemental material), suggesting that these effects do not depend on the cell context. Competitive EMSA combined with supershift assays indicated that PU.1 specifically binds to these sites in vitro (Fig. 2D , middle and right panels). Taken together, these results show that PU.1 transactivates the C/EBPε gene directly.
PML IV associates with PU.1 in vivo. To investigate the interaction of endogenous PML and PU.1, an immunoprecipitation assay was performed using HL-60 cells. An anti-PML antibody raised against its N terminus successfully immunoprecipitated multiple PML isoforms (Fig. 3A) from HL-60 cell extracts and also pulled down PU.1 together with them ( Fig.  3B, left) . Reciprocal experiments using an anti-PU.1 antibody revealed the predominant coimmunoprecipitation of a specific PML isoform with a molecular mass of ϳ75 kDa (Fig. 3B,  right) . These results indicate the association of these endogenous proteins in myeloid lineage cells. To determine the isoform specificity for PU.1 binding, PU.1 and one of each of the PML isoforms were transiently coexpressed and subjected to immunoprecipitation. PML II and IV specifically interacted with PU.1 (Fig. 3C ). An association between PU.1 and the other isoforms, including PML VI, was not successfully detected.
To further confirm those results, we next examined whether these two proteins are colocalized in cells (Fig. 3D ). Immunofluorescence revealed that PU.1 was spread throughout the nucleus in NIH 3T3 cells. Upon cotransfection with PML IV, however, PU.1 formed discrete speckles and colocalized prominently with PML IV PODs. Surprisingly, and in contrast with the immunoprecipitation results, PU.1 was not recruited to PML II PODs but instead was recruited to PML VI PODs. Colocalization of PU.1 with both PML IV and VI was also observed in HeLa cells (data not shown). We further examined the subcellular localization of both proteins in mouse embryonic fibroblasts from PML Ϫ/Ϫ mice. Here, we found that PU.1 was also recruited to PML IV PODs but not to PML VI PODs (see Fig. S2 in the supplemental material). These results suggest that the in vivo association between PU.1 and PML IV is of primary importance and that PML VI might indirectly associate with PU.1, although underlying mechanisms remain to be elucidated. PML IV specifically cooperates with PU.1 to induce terminal differentiation of L-G myeloblasts. We next investigated the ability of each PML isoform to cooperate with PU.1 in the terminal differentiation of L-G myeloid progenitor cells (16) . L-G cells were transfected with a vector for expressing PU.1 under the control of a metallothionein promoter (pMT-PU.1). We established several stable clones and confirmed that they morphologically differentiated toward polymorphonuclear cells (PMNs) upon the induction of PU.1 with ZnSO 4 . To investigate the isoform-specific cooperation between PU.1 and PML, we used a retrovirus to transduce the L-G/MT-PU.1 cells with PML I, II, III, IV, V, VI, or mock (L-G/MT-PU.1/PML isoforms) (Fig. 4A ). The level of PU.1 expression following induction with ZnSO 4 was the same in all seven cotransfected cells and the parent L-G/MT-PU.1 cells (see Fig. S3A in the supplemental material) (data not shown). Although the expression level of transduced PML IV seemed to be high compared to that of the endogenous one, it was almost comparable to the level of total PML expression (see Fig. S3C in the supplemental material). The induction of PU.1 expression alone retarded cell growth, and the coexpression of PML IV enhanced this effect (Fig. 4B ). PU.1 and PML IV also had a synergistic effect on morphological differentiation (Fig. 4C ). . It is noteworthy that the cooperativity of PU.1 and PML isoforms in granulocytic differentiation was comparable to their POD colocalization capability.
Next, we examined the effect of PML IV on PU.1 transcription activity. Luciferase reporter assays showed that among six PML isoforms, only PML IV had a marked effect on the activation of the C/EBPε reporter by PU.1 (Fig. 4D) . A parallel experiment using a reporter of the M-CSFR promoter also demonstrated a specific cooperation between PU.1 and PML IV, indicating that the interaction between these two proteins does not depend on the promoter context (see Fig. S3E in the supplemental material).
Moreover, we next examined whether PML IV could affect the expression of endogenous C/EBPε during PU.1-induced granulocytic differentiation (Fig. 4E) . In L-G/MT-PU.1/mock To confirm that PML IV enhancement of C/EBPε expression was due to transcriptional activation, quantitative RT-PCR was performed (Fig. 4F) . In L-G/MT-PU.1/PML IV cells, all six time points showed elevated C/EBPε transcripts compared to L-G/MT-PU.1/mock cells. The difference was more prominent before C/EBPε expression started to increase in L-G/MT-PU.1/mock cells.
We next investigated why more than 12 h was required before the induction of C/EBPε expression in LG/MT-PU.1 cells in spite of possible direct regulation by PU.1. Western blots showed that PU.1 induced the expression of endogenous PML in L-G/MT-PU.1 cells (Fig. 4G) . PML expression did not increase after ZnSO 4 RT-PCR analysis revealed that endogenous PML mRNA also increased (data not shown), PU.1 regulates PML expression, at least in part, at the transcriptional level. An important finding is that C/EBPε expression was also induced in a fashion parallel to that of PML expression in L-G/MT-PU.1 cells (Fig. 4G) . Together with the finding that the induction of C/EBPε becomes much faster when PML IV is already expressed exogenously (see Fig. S3H in the supplemental material), these results clearly indicate that PU.1 action on C/EBPε transcription is modulated by PML.
Structure-function relationship of the PU.1-PML IV interaction and its relevance in myeloid terminal differentiation. We performed coimmunoprecipitation assays to determine the region of PML required for the association with PU.1. Deletion of the C-terminal 13 amino acids of PML IV, which corresponds to the isoform-specific exon 8b, completely abolished the formation of the PU.1-PML complex (Fig. 5A ) (see Fig.  S4A in the supplemental material). The integrity of B boxes and the coiled-coil region was also required for an association with PU.1 (Fig. 5A ) (see Fig. S4A in the supplemental mate- rial). In addition, these C-terminally-deleted PML mutants could no longer recruit PU.1 to PODs in vivo (Fig. 5B) , nor could they enhance PU.1-mediated transcription (Fig. 5C ). Because the deletion mutant lacking exon 8b was unstable, and another one lacking exons 8a and 8b (PML IV⌬8ab) was not efficiently expressed in L-G cells (see Fig. S4B and S4C in the supplemental material), we used L-G/MT-PU.1 cells expressing PML lacking exons 7a, 8a, and 8b (PML IV⌬7a8ab) for further analysis (Fig. 5D) . In addition to losing the colocalization and transcriptional cooperation with PU.1, PML⌬7a8ab had no effect on the profile of PU.1-induced C/EBPε expression and cell differentiation (compare Fig. 5E and S4D and S4E in the supplemental material with Fig. 4B , C, and E). We also performed reciprocal experiments employing PU.1 mutants. Coimmunoprecipitation analysis using PU.1 deletion mutants showed that the acidic amino-acid-rich region (DE region) of the PU.1 transactivation domain is necessary for an association with PML IV (Fig. 6A ) (see Fig. S5A in the supplemental material). As expected, PML IV could no longer recruit PU.1 lacking the DE region (PU.1⌬DE) to PODs in vivo (Fig. 6B, top) , nor could it enhance PU.1⌬DE-mediated transcription, although PU.1⌬DE itself has a weak ability to enhance transcription (Fig. 6C , lanes 5 and 6). In agreement with these results, the expression of PU.1⌬DE did not effectively induce the expression of C/EBPε, and the overexpression of PML IV could not rescue the expression of C/EBPε (Fig.  6E, top) or significantly affect the differentiation of L-G cells (see Fig. S5D and S5E in the supplemental material).
To confirm the significance of the physical interaction between PU.1 and PML IV, we performed parallel experiments using a PU.1⌬PEST mutant that retains the ability to bind PML IV (see Fig. S5A in the supplemental material). In contrast to PU.1⌬DE, PML IV enhanced PU.1⌬PEST-mediated transcription to an extent similar to that of wild-type PU.1 (Fig.  6C, lanes 7 and 8) . PML IV also enhanced C/EBPε expression in L-G/MT-PU.1⌬PEST cells, although it did not affect the time course of C/EBPε expression (Fig. 6E, bottom) . This cooperation between PML IV and PU.1⌬PEST was also observed in the granulocytic differentiation of L-G cells (see Fig.  S5H and S5I in the supplemental material). Interestingly we noticed that PU.1⌬PEST expression in PML IV-transduced cells was maintained at a high level even after 48 h of treatment of ZnSO 4 compared to mock-transduced cells. RT-PCR analysis revealed that mRNA expression of PU.1⌬PEST was equal in both cells (see Fig. S5J in the supplemental material). These results suggest that PML IV enhances PU.1⌬PEST expression by a posttranscriptional mechanism.
Taken together, these results demonstrate that the specific interaction between PU.1 and PML IV is involved in their abilities to promote granulocytic differentiation.
PML IV promotes the association of PU.1 and p300 during granulocytic differentiation to form complexes for active expression of C/EBP. We next investigated the significance of the interaction of PU.1 and PML in regulating C/EBPε expression during granulocytic differentiation. In HL-60 cells, RA treatment immediately increased the expression of PU.1, PML, and p300 for 48 h (Fig. 7A) , which thereafter decreased (data not shown). The expression of all PML isoforms increased evenly. C/EBPε expression markedly increased for 48 h, whereas C/EBP␤ expression transiently increased and then returned to a level equal to that of untreated cells. To determine the interaction of the ternary complex of PU.1/PML/p300 on the C/EBPε promoter, ChIP analysis was performed (Fig.  7B) . Upon RA treatment, promoter-associated PU.1 modestly increased, and PML association gradually increased. A rapid recruitment of p300 within 24 h of RA treatment, which may be mediated by promoter-bound RAR through an RA-responsive element (RARE), was followed by further accumulation after 48 h of treatment. Note that the amount of p300 that coimmunoprecipitated with PU.1 was only minimally detected in untreated HL-60 cells but significantly increased within 48 h by RA treatment, and this increase was proportional to the amount of PML coimmunoprecipitation rather than the amount of PU.1 itself (Fig. 7C ). These results demonstrate that the ternary complex of PU.1/PML/p300 forms on the C/EBPε promoter and that the association of the complex increases in parallel to PML recruitment on the promoter during the early stage of granulocytic differentiation.
PU.1 alone induced C/EBPε expression, although relatively slowly, in L-G cells ( Fig. 4E and 7D ). An interesting finding is that C/EBPε expression was induced proportionally to p300 coimmunoprecipitation with PU.1. Another important finding is that the amount of p300 coimunnoprecipitation with PU.1 increased proportionally to the expression level of PML (Fig.  7D) . These results suggest a scaffold function of PML in the association of PU.1 and p300. To confirm this, the association of these proteins was further examined by immunoprecipitation experiments using a transient expression system. Although the interaction between p300 and PU.1 is seemingly enhanced by the coexpression of PML IV (Fig. 7E, top panels, lanes 3  and 4) , the coexpression of PML IV also increased PU.1 expression. These results raised the possibility that the increased coimmunoprecipitation of p300 may be due simply to an increased expression and availability of PU.1. To exclude this possibility, a reciprocal experiment was performed. Coimmunoprecipitation of PU.1 with p300 was not efficiently detected in the absence of PML IV but was easily observed when PML IV was coexpressed (Fig. 7E, middle panels, lanes 3 and 4) . On the other hand, the coexpression of PU.1 did not affect the interaction between p300 and PML IV (Fig. 7E, bottom panels, lanes 3 and 4) . These results suggest that the association of PU.1 and p300 is more labile than that of PML and p300 and support the data obtained in HL-60 cells showing that it can be stabilized by PML IV. We next performed immunofluorescence experiments to further confirm whether PU.1, p300, and PML form ternary complexes in vivo (Fig. 7F) . Whereas both PU.1 and p300 localized throughout the nucleus, they were concentrated in PODs when PML IV was coexpressed. We then investigated the cooperation of PML IV and p300 in PU.1-induced transcription by luciferase reporter assays (Fig.  7G) . PU.1 activation of the C/EBPε promoter was only slightly enhanced by the coexpression of p300 alone, but it was synergistically enhanced by the coexpression of PML IV and p300.
Notably, PU.1 was not efficiently recruited to abnormal nuclear aggregates of a sumoylation-deficient PML IV-3R mutant (see Fig. S6A in the supplemental material), even though PML IV-3R could still associate with PU.1 in immunoprecipitation experiments (data not shown). In contrast, p300 still efficiently colocalized with PML IV-3R. In agreement with its inability to recruit PU.1, PML IV-3R did not enhance PU.1 transactivation (see Fig. S6B in the supplemental material). These results suggest that a normal POD structure would be crucial for transcriptional synergism between PU.1 and PML IV.
PML-RARA disrupts active PU.1/PML/p300 transcriptional ternary complex. We next tested whether PML-RARA can affect PU.1-induced transcription. The C/EBPε promoter contains RARE. We found that whereas ligand-unbound RARA represses C/EBPε promoter activation, RA releases it to allow PU.1 to transactivate C/EBPε expression (see Fig. S7A in the supplemental material). PML-RARA also repressed promoter activity in the absence of RA (Fig. 8A) . We also found that the enhancement of PU.1-induced transcription by PML IV was greatly reduced by the coexpression of a much lower amount of PML-RARA, suggesting its potent dominant-negative effect on PML IV. In addition, PML-RARA repressed the transactivation by PU.1 even in the absence of exogenous coexpression of PML IV.
To determine whether the direct recruitment of PML-RARA to the promoter is required for its inhibitory effect, we performed transactivation experiments using the RARE-mutated (C/EBPε-mtRARE) reporter to which PML-RARA could no longer bind. Neither PML-RARA nor the RARA/retinoid X receptor affected the reporter activity in the absence of RA (data not shown); however, PML-RARA still dose-dependently inhibited both PU.1 transactivation and the PML IV enhancement of PU.1-induced transcription, similar to the wild-type reporter (Fig. 8B) . These results suggest that the inhibition of C/EBPε expression by PML-RARA is caused by the targeting of the PU.1-transcription factor complex. The M-CSFR promoter is also transrepressed by PML-RARA (data not shown), indicating that the effect of PML-RARA does not depend on the promoter context. Furthermore, PLZF-RARA, another APL-related chimera, disrupts the normal POD structure (20) and has effects that are similar to those of PML-RARA (see Fig. S7B in the supplemental material). These results suggest that the POD structure is required for PU.1 transactivation and is targeted by both chimeras.
To examine the inhibitory effects of PML-RARA on a different class of transcription factors, we performed parallel experiments using AML1b, which is functionally modulated by PML I (Fig. 8C) . In contrast to its effects on PU.1, PML-RARA only partially attenuated the PML I enhancement of AML1b transcription. To exclude the possibility that the inhibitory action of PML-RARA is directed towards PML IV function, another parallel experiment was performed. c-Myb was also associated with and superactivated by PML IV but not markedly affected by PML-RARA (data not shown). These results indicate that PML-RARA specifically targets the interaction of PU.1 and PML IV.
We next considered the underlying mechanism for the differences in the effects of PML-RARA on PU.1 and AML1b. Immunoprecipitation experiments revealed that in PU.1 immunoprecipitates, the amount of p300 was remarkably reduced and that PML IV was lost when PML-RARA was coexpressed (Fig. 8D, top) . In contrast, the coexpression of PML-RARA did not affect the amount of p300 coprecipitation but completely dissociated PU.1 from the PML IV immunoprecipitates (see Fig. S7C in the supplemental material) . On the other hand, analysis of the AML1b complex revealed that the amount of p300 coprecipitation was not affected by the coexpression of PML I and/or PML-RARA (Fig. 8D, lower panels) . The most striking difference was that PML-RARA coprecipitated with AML1b in the presence of PML I. Immunofluorescence analyses agreed with these results. PU.1 and AML1b were specifically colocalized in PML IV PODs and PML I PODs, respectively. When PML-RARA was coexpressed, the POD structures were disrupted, and PU.1 no longer colocalized with the PML IV microspeckles (Fig. 8E, top) , whereas AML1b still colocalized with PML I microspeckles (Fig. 8E, bottom) .
Finally, we examined the inhibition of PU.1-mediated granulocytic differentiation by PML-RARA in L-G/MT-PU.1 cells. The expression of PML-RARA in these cells (L-G/MT-PU.1/ MT-PML-RARA) markedly suppressed PU.1-induced C/ EBPε expression (Fig. 8F) . The induction of PU.1 expression never reduced cell proliferation in those cells (data not shown). Morphological examination revealed that the expression of PML-RARA caused L-G cells to take on the appearance of APL cells and eliminated the ability of PU.1 to cause granulocytic differentiation, resulting in a premature arrest of differentiation (Fig. 8G) .
DISCUSSION
In this study, we investigated the role of PML in myeloid differentiation and how the dominant-negative PML-RARA fusion affects the normal function of PML and gives rise to APL. Our results indicate the following: (i) PML cooperates with PU.1 to regulate C/EBPε expression during normal myeloid development, (ii) PML promotes the formation of an active transcription factor complex of PU.1 and p300 on the C/EBPε promoter during granulocytic differentiation, and (iii) PML-RARA has a dominant-negative effect not only on RA signaling but also on PML-induced transcription by disrupting the PU.1/PML/p300 ternary complex.
Role of PML in granuloid differentiation. PML is essential for RA action to induce terminal myeloid differentiation of precursor cells (32) . On the other hand, the role of RA signaling during myeloid development is still controversial. Although C/EBPε is one of the most promising targets to help elucidate (23), RARA Ϫ/Ϫ mice normally express C/EBPε and show normal granulopoiesis. Rather, neutrophil differentiation occurs faster for BM cells derived from RARA Ϫ/Ϫ mice than for those derived from wild-type mice (11) . These observations suggest that RARA is dispensable for granulopoiesis, and so the role of PML is other than to modulate the RA signaling. Granulopoiesis seems to be controlled by two pathways, at least in vitro, finally accompanying the increased expression of C/EBP families (37) . Insufficient granulopoiesis observed in PML Ϫ/Ϫ mice would be explained by the redundancy of the process itself or that of C/EBP␤ and C/EBPε function in addition to the regulatory rather than the mandatory function of PML. Contrary to data from a previous study (32) , we found that immature granulocytes increase in BM of PML Ϫ/Ϫ mice. This discrepancy may be due to a different set of antibodies used for flow cytometry, which successfully revealed this subtle difference, which was undetected by the differential counts on cytospin smears.
Since PU.1 expression can induce L-G cells to differentiate into mature granulocytes without any additional cytokines, it is likely that PU.1 activates an unrevealed transcription cascade(s) that directs terminal differentiation in a cell-autonomous manner. Although the P␤ promoter contains RARE, and C/EBPε is upregulated by a pharmacological dose of RA, at least in vitro (23) , RA treatment does not affect the DNase I hypersensitivity of P␤ (14) . Those findings imply that a transacting factor(s) other than the RAR would control the chromatin structure. Another interesting finding is that RA fails to induce the expression of C/EBPε in C/EBP␣-deficient cells (37) , suggesting that a C/EBP␣-initiating transcription cascade is responsible for RA signaling. Since PU.1 is one of the target genes induced by C/EBP␣ (31), it would be reasonable to speculate on the possible involvement of PU.1 in the regulation of C/EBPε. Taking our results of C/EBPε P␤ promoter analysis together with in vivo observations of RARA Ϫ/Ϫ mice (11), we propose a model that RAR would be a negative regulator to allow transcription upon RA binding and that Elucidation of PML and PU.1 interaction during granulocytic differentiation. Although each PML isoform resides within discrete subnuclear compartments, there have been few reports on their innate biological activities in myeloid development. In this study, overexpression experiments were employed to delineate the function of each PML isoform. Because their protein expression levels could not be equalized, it might be possible that PML II, III, and V isoforms could not represent significant synergistic action with PU.1 simply due to their insufficient availability. In addition, since the expression level of transduced PML IV seems to be high compared to that of the endogenous one, the effect of PML IV on PU.1 action should be carefully interpreted. On the other hand, we think that PML overexpression employed in this study may mimic, at least in part, the increase of PML isoforms during the early stage of terminal granulocytic differentiation. We observed that PU.1 and PML mutually regulate each other. Although the mechanism remains unclear, we speculate that the increase of PML expression during RA-induced granulocytic differentiation might be due, at least in part, to an increase of PU.1 expression. Although the issue of isoform change during differentiation seems to be very important, we think at present that during granulocytic differentiation, PML (and PML IV) is regulated mainly quantitatively. In turn, PML IV specifically associates with PU.1 in vivo and enhances its function. Thus, PU.1 autoregulates its own transcriptional capability. The isoform-specific interaction was closely linked to the functional cooperation of PML and PU.1. Note that the ternary complex formation of PU.1/PML/p300 on the C/EBPε promoter depends on PML recruitment and that it occurs rapidly after RA treatment, suggesting its role at the early stage of granulocytic terminal differentiation.
On the other hand, the relevance of the POD structure to transcriptional control remains elusive. Sumoylation of PML IV is a prerequisite for the normal architecture of PODs (39) and seems to be crucial for the transcriptional regulation of the PU.1/PML/p300 complex. Furthermore, the B boxes and coiled-coil domain of PML, essential for the formation of the normal POD structure, were required for the colocalization of PU.1 with PML IV. We also observed that PML VI cannot efficiently associate with PU.1 but does recruit it to PODs, and this activity is correlated with the cooperation of these proteins in the granulocytic differentiation of L-G cells, although PML VI does so less efficiently than PML IV. We speculate that PML VI indirectly regulates PU.1; e.g., PML VI may promote PML IV-mediated PU.1 targeting to PODs, although a complete understanding of the interaction between PML isoforms remains challenging. Another interesting finding is that PML IV augmented only the amount of C/EBPε expression but did not affect its time course profile in L-G cells expressing PU.1⌬PEST. Taken together with the finding that PU.1⌬PEST could not be efficiently recruited to PODs, we believe at present that PML IV-mediated ternary complex formation within the structurally integrated PODs would be required for the synergistic activation of transcription by the PU.1/PML/ p300 ternary complex in vivo.
PU.1 and p300/CBP can directly interact, at least in vitro (33) ; however, we found that their association is rather weak compared with those of other transcription factors such as AML1b. We demonstrated that the PU.1/PML/p300 ternary complex is also formed on the target gene promoter and speculate that both PU.1 and p300 are efficiently assembled with the aid of PML IV, leading to the synergistic transcriptional activation of the target gene. As observed in LG/MT-PU.1 cells, efficient C/EBPε expression cannot be induced by PU.1 alone but requires the increase of PML expression and a possible reorganization of the PU.1 complex into an active form. We also observed that PML IV increases PU.1 expression in both transient and stable coexpression systems throughout our experiments. Although its molecular mechanism remains to be elucidated, we speculate that the PML enhancement of PU.1 activity has an additional aspect of increased availability of PU.1 in addition to promoting the formation of the active transcription factor complex. Thus, PML IV seems to modulate PU.1 activity by both qualitative and quantitative mechanisms.
Reconsideration of the role of PML-RARA in APL: PML-RARA as a dominant-negative mutant causing dissociation of the PML-mediated transcription factor complex. Because RARA is a target for all APL-related chromosomal translocations, an alteration of its function must be required for promyelocytic transformation. PML-RARA has been thought to act as a dominant-negative inhibitor of the transactivator function of RARA. In addition, PML is a component of ligandbound RARA complexes and regulates their activity (38) . These observations have led to a proposed model in which PML-RARA acts as a dominant-negative inhibitor of the RA signaling pathway at multiple steps. On the other hand, since RARA has turned out to be dispensable for granulopoiesis, or rather acts as a transrepressor under physiological conditions in vivo (11) , the enhanced repression of RA signals by PML-RARA would not likely be sufficient for fully elucidating the molecular mechanism of differentiation arrest in APL. It is not surprising, therefore, that the HDAC1-RARA fusion protein, a bona fide dominant-negative form of RARA, does not cause a block in myeloid differentiation in vivo and was not leukemogenic in those transgenic mice (18) . Another study showed that homodimerizing artificial RAR fusions alone are poor initiators of leukemia, characterized by significant leukocytosis of mature neutrophils in vivo (28) . Rather, the main role of the inhibitory effect of PML-RARA in RA signaling might only be priming for APL-like leukemia by the attenuation of spontaneous apoptosis (15) . Therefore, the inhibitory roles of PML-RARA in normal PML function should be responsible for differentiation arrest.
We propose two different modes of action for PML-RARA inhibiting PML/transcription factor complexes (Fig. 8H) . Because the association between PU.1 and p300 is weak, and largely depends on PML, PML-RARA heterodimerizes with PML and sequesters the PML/p300 complex from PU.1 (type I dominant-negative inhibition). On the other hand, AML1b still forms a stable complex with p300 regardless of the presence of PML I. In this case, PML-RARA gathers on the AML1b/p300 complex through heterodimerization with PML I and then attenuates the transcriptional activity, probably by recruiting corepressor complexes to overcome the histone acetyltransferase activity of p300/CBP (type II inhibition).
Thus, the inhibitory effects of PML-RARA would depend largely on the stability of a given transcription factor/p300 complex for PML.
Several lines of evidence suggest roles for C/EBPε in APL pathogenesis. Differentiation of BM cells from C/EBPε Ϫ/Ϫ mice is practically arrested at the promyelocyte stage, at least in vitro (34a). In addition, a previous excellent study shows that the overexpression of C/EBPε in APL rescues differentiation arrest in vitro as well as in vivo and prolongs the survival of mice transplanted with APL cells (29) . On the other hand, repression of C/EBPε does not fully account for the pathophysiology of APL, because C/EBPε Ϫ/Ϫ mice do not capture the APL phenotype. Walter et al. previously reported that reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARA (30) . Those authors also demonstrated that PML-RARA decreases the expression of PU.1 mRNA in PU.1-haploinsuficient mice by unknown mechanisms, causing the development of a hypomorphic PU.1 phenotype. Because PU.1 autoregulates its own expression (1), our results showing that PML-RARA inhibits the transcriptional capability of PU.1 agree with their findings and might partly explain the graded reduction of physiological PU.1 below a critical level, followed by the induction of myeloid leukemia (26) . Thus, we suppose that the repression of PU.1 is one of the crucial mechanisms in PML-RARA leukemogenesis. Furthermore, PML-RARA is a multivalent suppressor for other C/EBP family members, including C/EBP␣ and C/EBP␤ (4, 24, 29) . We think that comprehensive inhibition of those transcription factors might be responsible for the full manifestation of APL.
There are four other types of APL-related chimeras that have been reported. Among them, NPM-or NuMA-RARA fusions do not affect the POD structure (8) . In this respect, PML localization itself is not of primary importance for APL pathogenesis. On the other hand, disruption of the POD structure into microspeckles is invariably observed in t(15;17)-bearing APL, and the restoration of normal POD architecture is an early event in granulocytic differentiation following RA-induced degradation of PML-RARA (35) . Therefore, POD structure-based PML function still seems to be a key target for the pathogenesis of PML-RARA-induced APL.
